📊 OCUL Key Takeaways
Is Ocular Therapeutix, Inc. (OCUL) a Good Investment?
Ocular Therapeutix exhibits critical fundamental deterioration with -$265.9M net loss, -18.5% revenue decline YoY, and -$204.9M operating cash burn rate eroding the substantial $737.1M cash position. At current burn rates, the company has approximately 3.6 years of cash runway, yet declining revenue indicates weakening business fundamentals rather than temporary R&D investments maturing into growth.
OCULAR THERAPEUTIX has a strong, low-leverage balance sheet with ~$737M in cash and very high liquidity, providing a multi-year runway. However, fundamentals are weak: revenue declined 18.5% YoY and margins are extremely negative, driving heavy operating and free-cash-flow losses. Until revenue re-accelerates and operating losses compress materially, the risk-reward on fundamentals remains unfavorable.
Why Buy Ocular Therapeutix, Inc. Stock? OCUL Key Strengths
- Strong balance sheet with $737.1M in cash equivalents providing liquidity cushion
- Minimal leverage with 0.04x Debt/Equity ratio reducing financial distress risk
- Stockholders equity of $654.3M offers financial stability for operations and clinical development
- Exceptional liquidity (current ratio ~15x; cash ~$737M) provides runway
- Minimal leverage (D/E ~0.04x) reduces solvency risk
- Large equity base relative to liabilities supports resilience
OCUL Stock Risks: Ocular Therapeutix, Inc. Investment Risks
- Revenue declining 18.5% YoY signals market headwinds, reduced demand, or commercial execution challenges
- Operating cash burn of -$204.9M annually is unsustainable without revenue inflection or successful capital raises
- Operating margin of -519.8% and net margin of -511.9% indicate fundamental profitability issues with no clear path to breakeven
- Severe and persistent losses (operating margin ~-520%, FCF margin ~-418%)
- Revenue contraction (-18.5% YoY) signals weak commercial traction
- Sustained cash burn could lead to future dilution once runway shortens
Key Metrics to Watch
- Revenue growth reversal - must demonstrate stabilization and YoY growth to reverse trajectory
- Operating cash flow improvement - critical indicator of progress toward sustainable operations
- Cash depletion rate - determines financing runway and potential shareholder dilution from future capital raises
- Revenue growth trajectory (quarterly YoY/seq)
- Operating cash burn and operating margin improvement
Ocular Therapeutix, Inc. (OCUL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.39x current ratio provides a solid financial cushion.
OCUL Profit Margin, ROE & Profitability Analysis
OCUL vs Healthcare Sector: How Ocular Therapeutix, Inc. Compares
How Ocular Therapeutix, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ocular Therapeutix, Inc. Stock Overvalued? OCUL Valuation Analysis 2026
Based on fundamental analysis, Ocular Therapeutix, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ocular Therapeutix, Inc. Balance Sheet: OCUL Debt, Cash & Liquidity
OCUL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ocular Therapeutix, Inc.'s revenue has grown significantly by 46% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.02 indicates the company is currently unprofitable.
OCUL Revenue Growth, EPS Growth & YoY Performance
OCUL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.5M | -$36.5M | $-0.22 |
| Q2 2025 | $13.5M | -$43.8M | $-0.26 |
| Q1 2025 | $10.7M | -$64.1M | $-0.38 |
| Q3 2024 | $15.1M | -$516.0K | $-0.22 |
| Q2 2024 | $15.2M | -$20.7M | $-0.26 |
| Q1 2024 | $13.4M | -$30.3M | $-0.39 |
| Q3 2023 | $12.0M | -$516.0K | $-0.25 |
| Q2 2023 | $12.3M | -$12.5M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ocular Therapeutix, Inc. Dividends, Buybacks & Capital Allocation
OCUL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ocular Therapeutix, Inc. (CIK: 0001393434)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OCUL
What is the AI rating for OCUL?
Ocular Therapeutix, Inc. (OCUL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OCUL's key strengths?
Claude: Strong balance sheet with $737.1M in cash equivalents providing liquidity cushion. Minimal leverage with 0.04x Debt/Equity ratio reducing financial distress risk. ChatGPT: Exceptional liquidity (current ratio ~15x; cash ~$737M) provides runway. Minimal leverage (D/E ~0.04x) reduces solvency risk.
What are the risks of investing in OCUL?
Claude: Revenue declining 18.5% YoY signals market headwinds, reduced demand, or commercial execution challenges. Operating cash burn of -$204.9M annually is unsustainable without revenue inflection or successful capital raises. ChatGPT: Severe and persistent losses (operating margin ~-520%, FCF margin ~-418%). Revenue contraction (-18.5% YoY) signals weak commercial traction.
What is OCUL's revenue and growth?
Ocular Therapeutix, Inc. reported revenue of $52.0M.
Does OCUL pay dividends?
Ocular Therapeutix, Inc. does not currently pay dividends.
Where can I find OCUL SEC filings?
Official SEC filings for Ocular Therapeutix, Inc. (CIK: 0001393434) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OCUL's EPS?
Ocular Therapeutix, Inc. has a diluted EPS of $-1.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OCUL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ocular Therapeutix, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OCUL stock overvalued or undervalued?
Valuation metrics for OCUL: ROE of -40.6% (sector avg: 15%), net margin of -511.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OCUL stock in 2026?
Our dual AI analysis gives Ocular Therapeutix, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OCUL's free cash flow?
Ocular Therapeutix, Inc.'s operating cash flow is $-204.9M, with capital expenditures of $12.0M. FCF margin is -417.5%.
How does OCUL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -511.9% (avg: 12%), ROE -40.6% (avg: 15%), current ratio 15.39 (avg: 2).